NJ State Employees Deferred Compensation Plan held its stake in Bristol-Myers Squibb Company (NYSE:BMY) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 26,884 shares of the biopharmaceutical company’s stock at the close of the second quarter. NJ State Employees Deferred Compensation Plan’s holdings in Bristol-Myers Squibb were worth $1,498,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Toronto Dominion Bank lifted its holdings in shares of Bristol-Myers Squibb by 54.0% in the 1st quarter. Toronto Dominion Bank now owns 464,591 shares of the biopharmaceutical company’s stock valued at $25,264,000 after acquiring an additional 162,884 shares during the last quarter. Mutual of America Capital Management LLC lifted its holdings in shares of Bristol-Myers Squibb by 1.9% in the 1st quarter. Mutual of America Capital Management LLC now owns 201,037 shares of the biopharmaceutical company’s stock valued at $10,932,000 after acquiring an additional 3,833 shares during the last quarter. Meridian Management Co. lifted its holdings in shares of Bristol-Myers Squibb by 1.5% in the 1st quarter. Meridian Management Co. now owns 51,770 shares of the biopharmaceutical company’s stock valued at $2,815,000 after acquiring an additional 770 shares during the last quarter. Quantitative Investment Management LLC bought a new position in shares of Bristol-Myers Squibb in the 1st quarter valued at about $6,150,000. Finally, Tobam lifted its holdings in shares of Bristol-Myers Squibb by 124.5% in the 1st quarter. Tobam now owns 793,714 shares of the biopharmaceutical company’s stock valued at $43,163,000 after acquiring an additional 440,170 shares during the last quarter. 68.87% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “Bristol-Myers Squibb Company (BMY) Stake Maintained by NJ State Employees Deferred Compensation Plan” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/10/09/bristol-myers-squibb-company-bmy-stake-maintained-by-nj-state-employees-deferred-compensation-plan.html.

Several analysts have issued reports on the stock. Vetr downgraded shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $64.20 price objective for the company. in a research note on Tuesday, August 22nd. Deutsche Bank AG set a $55.00 price objective on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a research note on Monday, July 17th. Credit Suisse Group set a $58.00 price objective on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a research note on Wednesday, August 16th. Jefferies Group LLC reissued a “buy” rating and issued a $63.00 price objective on shares of Bristol-Myers Squibb in a research note on Wednesday, July 12th. Finally, Cowen and Company set a $65.00 price objective on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a research note on Monday, August 14th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and ten have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $62.38.

In other news, SVP Joseph C. Caldarella sold 9,340 shares of the company’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total value of $560,400.00. Following the transaction, the senior vice president now directly owns 46,297 shares in the company, valued at approximately $2,777,820. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Theodore R. Samuels II acquired 6,000 shares of the firm’s stock in a transaction dated Wednesday, August 2nd. The stock was bought at an average price of $55.94 per share, for a total transaction of $335,640.00. Following the completion of the acquisition, the director now owns 18,000 shares in the company, valued at approximately $1,006,920. The disclosure for this purchase can be found here. Corporate insiders own 0.23% of the company’s stock.

Bristol-Myers Squibb Company (NYSE BMY) opened at 64.81 on Monday. The stock’s 50 day moving average is $61.56 and its 200-day moving average is $56.65. The stock has a market capitalization of $106.28 billion, a price-to-earnings ratio of 23.67 and a beta of 1.19. Bristol-Myers Squibb Company has a 12 month low of $46.01 and a 12 month high of $65.03.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $0.74 EPS for the quarter, topping the consensus estimate of $0.73 by $0.01. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. The firm had revenue of $5.14 billion for the quarter, compared to analyst estimates of $5.09 billion. During the same period in the prior year, the business posted $0.69 EPS. The business’s revenue for the quarter was up 5.6% compared to the same quarter last year. On average, equities research analysts expect that Bristol-Myers Squibb Company will post $2.98 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 1st. Stockholders of record on Friday, October 6th will be issued a $0.39 dividend. The ex-dividend date of this dividend is Thursday, October 5th. This represents a $1.56 annualized dividend and a dividend yield of 2.41%. Bristol-Myers Squibb’s dividend payout ratio is currently 56.73%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Stock Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related stocks with our FREE daily email newsletter.